Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Best, P. J.M.
space
  arrow  Lerman, A.
space
 arrow  PubMed                        
space

REPLY

Effect of Estrogen on Nitric Oxide and Endothelin-1

right arrow Patricia J.M. Best, MD, and Amir Lerman, MD

15 July 1998 | Volume 129 Issue 2 | Page 160


IN RESPONSE:

As Dr. Brody notes, increasing evidence supports endothelin-1 as an atherosclerotic peptide. Not only are both circulating and tissue levels of endothelin-1 increased in patients with atherosclerosis, but the effects of endothelin-1 are enhanced in pathophysiologic states [1]. In addition, we have shown that endothelin-1 is present in human atherectomy specimens and after mechanical pressure or after stretch endothelin-1 is released. Endothelin-1 has vasoconstricting and proliferative properties that antagonize the effects of nitric oxide. Furthermore, the regulation of endothelin-1 and the regulation of nitric oxide are linked. Because the interrelation between these two vasoactive substances is functionally significant, further study of the effects of therapy on both of these systems will be important.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Mayo Clinic and Foundation; Rochester, MN 55905


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991; 325:997-1001.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Best, P. J.M.
space
  arrow  Lerman, A.
space
 arrow  PubMed                        
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online